Avadel Pharmaceuticals Plc ADR (AVDL)
8.30 x 12 8.89 x 1
Pre-market by (Cboe BZX)
8.77 +0.17 (+1.98%) 04/25/25 [NASDAQ]
8.30 x 12 8.89 x 1
Pre-market 8.77 unch (unch) 16:00 ET
for Fri, Apr 25th, 2025
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
Cash Flows From Operating Activities | |||||
Net Income | -48,832 | -160,276 | -137,464 | -77,329 | 7,028 |
Depreciation Amortization | 2,681 | 1,766 | 1,493 | 815 | 1,690 |
Income taxes - deferred | N/A | N/A | 26,025 | -15,666 | -7,431 |
Accounts receivable | -21,994 | -12,103 | N/A | N/A | 8,281 |
Accounts payable and accrued liabilities | -4,093 | 1,545 | -3,108 | 4,232 | -2,788 |
Other Working Capital | -20,315 | -2,999 | 24,535 | 3,695 | -14,324 |
Other Operating Activity | 45,646 | 43,556 | 18,215 | 6,943 | -41,190 |
Operating Cash Flow | $-46,907 | $-128,511 | $-70,304 | $-77,310 | $-48,734 |
Cash Flows From Investing Activities | |||||
Change In Deposits | 51,780 | -50,093 | 80,414 | 40,455 | -95,123 |
PPE Investments | N/A | N/A | -716 | -26 | -98 |
Net Acquisitions | N/A | N/A | N/A | 16,500 | 25,500 |
Investing Cash Flow | $51,780 | $-50,093 | $79,698 | $56,929 | $-69,721 |
Cash Flows From Financing Activities | |||||
Common Stock Issued | 15,970 | 148,357 | 28,000 | 263 | 179,683 |
Other Financing Activity | 0 | -13,022 | -13,457 | 0 | 0 |
Financing Cash Flow | $15,970 | $135,335 | $14,543 | $263 | $179,683 |
Exchange Rate Effect | -639 | 455 | -664 | -896 | 720 |
Beginning Cash Position | 31,167 | 73,981 | 50,708 | 71,722 | 9,774 |
End Cash Position | 51,371 | 31,167 | 73,981 | 50,708 | 71,722 |
Net Cash Flow | $20,204 | $-42,814 | $23,273 | $-21,014 | $61,948 |
Free Cash Flow | |||||
Operating Cash Flow | -46,907 | -128,511 | -70,304 | -77,310 | -48,734 |
Capital Expenditure | N/A | N/A | -716 | -26 | -98 |
Free Cash Flow | -46,907 | -128,511 | -71,020 | -77,336 | -48,832 |